Abbott Laboratories (NYSE:ABT) Stock Holdings Increased by UMB Bank N A MO


Share on StockTwits

UMB Bank N A MO increased its position in shares of Abbott Laboratories (NYSE:ABT) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 321,990 shares of the healthcare product maker’s stock after acquiring an additional 4,599 shares during the quarter. Abbott Laboratories accounts for about 0.9% of UMB Bank N A MO’s holdings, making the stock its 23rd largest position. UMB Bank N A MO’s holdings in Abbott Laboratories were worth $38,587,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Cribstone Capital Management LLC raised its holdings in shares of Abbott Laboratories by 1.2% during the fourth quarter. Cribstone Capital Management LLC now owns 6,796 shares of the healthcare product maker’s stock valued at $744,000 after acquiring an additional 83 shares during the period. Axiom Financial Strategies LLC raised its holdings in shares of Abbott Laboratories by 4.4% during the fourth quarter. Axiom Financial Strategies LLC now owns 2,027 shares of the healthcare product maker’s stock valued at $222,000 after acquiring an additional 86 shares during the period. Ocean Capital Management LLC raised its holdings in shares of Abbott Laboratories by 2.4% during the fourth quarter. Ocean Capital Management LLC now owns 3,783 shares of the healthcare product maker’s stock valued at $414,000 after acquiring an additional 87 shares during the period. Cohen Lawrence B raised its holdings in shares of Abbott Laboratories by 1.2% during the fourth quarter. Cohen Lawrence B now owns 7,608 shares of the healthcare product maker’s stock valued at $833,000 after acquiring an additional 89 shares during the period. Finally, Aspen Investment Management Inc raised its holdings in shares of Abbott Laboratories by 0.8% during the fourth quarter. Aspen Investment Management Inc now owns 11,080 shares of the healthcare product maker’s stock valued at $1,213,000 after acquiring an additional 90 shares during the period. Institutional investors and hedge funds own 72.58% of the company’s stock.

In other news, SVP Joseph J. Manning sold 18,750 shares of the business’s stock in a transaction that occurred on Monday, February 1st. The stock was sold at an average price of $122.79, for a total value of $2,302,312.50. Following the transaction, the senior vice president now directly owns 81,561 shares of the company’s stock, valued at approximately $10,014,875.19. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mary K. Moreland sold 505 shares of the business’s stock in a transaction that occurred on Tuesday, February 16th. The stock was sold at an average price of $128.49, for a total value of $64,887.45. Following the completion of the transaction, the executive vice president now directly owns 63,878 shares in the company, valued at $8,207,684.22. The disclosure for this sale can be found here. Insiders have sold 27,476 shares of company stock worth $3,366,543 over the last 90 days. Corporate insiders own 1.70% of the company’s stock.

Shares of ABT opened at $124.35 on Friday. Abbott Laboratories has a 12-month low of $86.16 and a 12-month high of $128.54. The company has a quick ratio of 1.19, a current ratio of 1.70 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $220.29 billion, a price-to-earnings ratio of 65.79, a P/E/G ratio of 2.06 and a beta of 0.83. The stock’s 50-day moving average price is $119.52 and its 200 day moving average price is $113.97.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Tuesday, January 26th. The healthcare product maker reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.10. Abbott Laboratories had a return on equity of 18.19% and a net margin of 10.50%. The firm had revenue of $10.70 billion for the quarter, compared to analyst estimates of $9.94 billion. During the same period in the previous year, the company posted $0.95 earnings per share. The company’s quarterly revenue was up 28.7% compared to the same quarter last year. Equities research analysts expect that Abbott Laboratories will post 3.57 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, May 17th. Investors of record on Thursday, April 15th will be paid a dividend of $0.45 per share. The ex-dividend date is Wednesday, April 14th. This represents a $1.80 annualized dividend and a yield of 1.45%. Abbott Laboratories’s dividend payout ratio is 55.56%.

Several research analysts have weighed in on ABT shares. Morgan Stanley upped their price objective on shares of Abbott Laboratories from $126.00 to $136.00 and gave the company an “overweight” rating in a research note on Thursday, January 28th. Credit Suisse Group upped their price objective on shares of Abbott Laboratories from $118.00 to $130.00 and gave the company an “outperform” rating in a research note on Thursday, January 28th. Atlantic Securities began coverage on shares of Abbott Laboratories in a research note on Thursday. They issued a “neutral” rating and a $122.00 price objective on the stock. BTIG Research raised shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and set a $140.00 price objective for the company in a research note on Thursday, January 28th. Finally, Raymond James raised their target price on Abbott Laboratories from $126.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday, March 17th. One research analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have given a buy rating to the stock. Abbott Laboratories currently has a consensus rating of “Buy” and an average price target of $124.39.

Abbott Laboratories Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Read More: What is a good rate of return for a mutual fund?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.